254 related articles for article (PubMed ID: 36531688)
1. Biglycan as a mediator of proinflammatory response and target for MDS and sAML therapy.
Vaxevanis CK; Bauer M; Subbarayan K; Friedrich M; Massa C; Biehl K; Al-Ali HK; Wickenhauser C; Seliger B
Oncoimmunology; 2023; 12(1):2152998. PubMed ID: 36531688
[TBL] [Abstract][Full Text] [Related]
2. CXCL12+ stromal cells as bone marrow niche for CD34+ hematopoietic cells and their association with disease progression in myelodysplastic syndromes.
Abe-Suzuki S; Kurata M; Abe S; Onishi I; Kirimura S; Nashimoto M; Murayama T; Hidaka M; Kitagawa M
Lab Invest; 2014 Nov; 94(11):1212-23. PubMed ID: 25199050
[TBL] [Abstract][Full Text] [Related]
3. Altered Spatial Composition of the Immune Cell Repertoire in Association to CD34
Bauer M; Vaxevanis C; Al-Ali HK; Jaekel N; Naumann CLH; Schaffrath J; Rau A; Seliger B; Wickenhauser C
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33430322
[No Abstract] [Full Text] [Related]
4. Oxidized Mitochondrial DNA Engages TLR9 to Activate the NLRP3 Inflammasome in Myelodysplastic Syndromes.
Ward GA; Dalton RP; Meyer BS; McLemore AF; Aldrich AL; Lam NB; Onimus AH; Vincelette ND; Trinh TL; Chen X; Calescibetta AR; Christiansen SM; Hou HA; Johnson JO; Wright KL; Padron E; Eksioglu EA; List AF
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835307
[TBL] [Abstract][Full Text] [Related]
5. Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy.
Radujkovic A; Dietrich S; Andrulis M; Benner A; Longerich T; Pellagatti A; Nanda K; Giese T; Germing U; Baldus S; Boultwood J; Ho AD; Dreger P; Luft T
Int J Cancer; 2016 Sep; 139(6):1402-13. PubMed ID: 27170453
[TBL] [Abstract][Full Text] [Related]
6. The nonsteroidal anti-inflammatory drug Exisulind selectively induces apoptosis via JNK in secondary acute myeloid leukemia after myelodysplastic syndrome.
Czibere A; Prall WC; Zerbini LF; Grall F; Craigie EC; Ulrich SD; Giagounidis AA; Haas R; Libermann TA; Aivado M
Cell Cycle; 2005 Jun; 4(6):812-7. PubMed ID: 15970671
[TBL] [Abstract][Full Text] [Related]
7. Apparent expansion of CD34+ cells during the evolution of myelodysplastic syndromes to acute myeloid leukemia.
Span LF; Dar SE; Shetty V; Mundle SD; Broady-Robinson L; Alvi S; Raymakers RA; de Witte T; Raza A
Leukemia; 1998 Nov; 12(11):1685-95. PubMed ID: 9823942
[TBL] [Abstract][Full Text] [Related]
8. Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival.
Corradi G; Baldazzi C; Očadlíková D; Marconi G; Parisi S; Testoni N; Finelli C; Cavo M; Curti A; Ciciarello M
Stem Cell Res Ther; 2018 Oct; 9(1):271. PubMed ID: 30359303
[TBL] [Abstract][Full Text] [Related]
9. Characterization of myelodysplastic syndromes hematopoietic stem and progenitor cells using mass cytometry.
Bachas C; Duetz C; van Spronsen MF; Verhoeff J; Garcia Vallejo JJ; Jansen JH; Cloos J; Westers TM; van de Loosdrecht AA
Cytometry B Clin Cytom; 2023 Mar; 104(2):128-140. PubMed ID: 35289472
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the prognostic relevance of L-selectin and ICAM1 expression in myelodysplastic syndromes.
Buccisano F; Maurillo L; Tamburini A; Del Poeta G; Del Principe MI; Ammatuna E; Consalvo MI; Campagna S; Ottaviani L; Sarlo C; Renzi D; Faccia S; Fraboni D; Lo Coco F; Amadori S; Venditti A
Eur J Haematol; 2008 Feb; 80(2):107-14. PubMed ID: 18028430
[TBL] [Abstract][Full Text] [Related]
11. Intracellular ROS profile in hematopoietic progenitors of MDS patients: association with blast count and iron overload.
Chan LSA; Gu LC; Leitch HA; Wells RA
Hematology; 2021 Dec; 26(1):88-95. PubMed ID: 34000978
[No Abstract] [Full Text] [Related]
12. Secretion and Expression of Matrix Metalloproteinase-2 and 9 from Bone Marrow Mononuclear Cells in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Chaudhary AK; Chaudhary S; Ghosh K; Shanmukaiah C; Nadkarni AH
Asian Pac J Cancer Prev; 2016; 17(3):1519-29. PubMed ID: 27039800
[TBL] [Abstract][Full Text] [Related]
13. Biglycan, a danger signal that activates the NLRP3 inflammasome via toll-like and P2X receptors.
Babelova A; Moreth K; Tsalastra-Greul W; Zeng-Brouwers J; Eickelberg O; Young MF; Bruckner P; Pfeilschifter J; Schaefer RM; Gröne HJ; Schaefer L
J Biol Chem; 2009 Sep; 284(36):24035-48. PubMed ID: 19605353
[TBL] [Abstract][Full Text] [Related]
14. Cellular senescence induced by S100A9 in mesenchymal stromal cells through NLRP3 inflammasome activation.
Shi L; Zhao Y; Fei C; Guo J; Jia Y; Wu D; Wu L; Chang C
Aging (Albany NY); 2019 Nov; 11(21):9626-9642. PubMed ID: 31727865
[TBL] [Abstract][Full Text] [Related]
15. Pretreatment CD34
Jentzsch M; Geus U; Grimm J; Vucinic V; Pönisch W; Franke GN; Behre G; Niederwieser D; Schwind S
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1560-1566. PubMed ID: 30928626
[TBL] [Abstract][Full Text] [Related]
16. TNFα induces Caspase-3 activity in hematopoietic progenitor cells CD34+, CD33+, and CD41 + of myelodysplastic syndromes.
Iriani A; Rachman A; Setiabudy RD; Kresno SB; Sudoyo AW; Arief M; Harahap AR; Fatina MK
BMC Mol Cell Biol; 2023 Nov; 24(1):33. PubMed ID: 37990142
[TBL] [Abstract][Full Text] [Related]
17. Increased apoptosis in mononucleated cells but not in CD34+ cells in blastic forms of myelodysplastic syndromes.
Berger G; Hunault-Berger M; Rachieru P; Fontenay-Roupie M; Baranger L; Ifrah N; Zandecki M
Hematol J; 2001; 2(2):87-96. PubMed ID: 11424000
[TBL] [Abstract][Full Text] [Related]
18. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis.
Stifter G; Heiss S; Gastl G; Tzankov A; Stauder R
Eur J Haematol; 2005 Dec; 75(6):485-91. PubMed ID: 16313260
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study.
Granfeldt Østgård LS; Medeiros BC; Sengeløv H; Nørgaard M; Andersen MK; Dufva IH; Friis LS; Kjeldsen E; Marcher CW; Preiss B; Severinsen M; Nørgaard JM
J Clin Oncol; 2015 Nov; 33(31):3641-9. PubMed ID: 26304885
[TBL] [Abstract][Full Text] [Related]
20. U2AF1 mutation promotes tumorigenicity through facilitating autophagy flux mediated by FOXO3a activation in myelodysplastic syndromes.
Zhu Y; Song D; Guo J; Jin J; Tao Y; Zhang Z; Xu F; He Q; Li X; Chang C; Wu L
Cell Death Dis; 2021 Jun; 12(7):655. PubMed ID: 34183647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
